Víctor Fraile-Ágreda

Mr. Víctor Fraile-Ágreda

Pediatrics, UConn Health Center, Farmington, Connecticut, USA
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2024 in Cell
Verified
Journal Article
Closed access
SWSkylar S. Wright
Skylar S. Wright
PKPuja Kumari
Puja Kumari
Víctor Fraile-ÁgredaVíctor Fraile-Ágreda
Víctor Fraile-Ágreda
CWChengliang Wang
Chengliang Wang
SSSonia Shivcharan
Sonia Shivcharan
VRVijay A. Rathinam
Vijay A. Rathinam

16 November 2023 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
PKPuja Kumari
Puja Kumari
SVSwathy O. Vasudevan
Swathy O. Vasudevan
ARAshley J. Russo
Ashley J. Russo
SWSkylar S. Wright
Skylar S. Wright
Víctor Fraile-ÁgredaVíctor Fraile-Ágreda
Víctor Fraile-Ágreda
VRVijay A. Rathinam
Vijay A. Rathinam

Verified
Journal Article
Open access
PDF file
Víctor Fraile-ÁgredaVíctor Fraile-Ágreda
Víctor Fraile-Ágreda
OCOlga Cañadas
Olga Cañadas
TWTimothy E. Weaver
Timothy E. Weaver
CCCristina Casals
Cristina Casals
As key components of innate immunity, lung antimicrobial proteins play a critical role in warding off invading respiratory pathogens. Lung surfactant protein A (SP-A) exerts synergistic antimicrobial activity with the N-terminal segment of the SP-B proprotein (SP-BN) against Klebsiella pneumoniae K2 in vivo. However, the factors that govern SP-A/SP-BN antimicrobial activity are still unclear. The aim of this study was to identify the mechanisms by which SP-A and SP-BN act synergistically against K. pneumoniae, which is resistant to either protein alone. The effect of these proteins on K. pneumoniae was studied by membrane permeabilization and depolarization assays and transmission electron microscopy. Their effects on model membranes of the outer and inner bacterial membranes were analyzed by differential scanning calorimetry and membrane leakage assays. Our results indicate that the SP-A/SP-BN complex alters the ultrastructure of K. pneumoniae by binding to lipopolysaccharide molecules present in the outer membrane, forming packing defects in the membrane that may favor the translocation of both proteins to the periplasmic space. The SP-A/SP-BN complex depolarized and permeabilized the inner membrane, perhaps through the induction of toroidal pores. We conclude that the synergistic antimicrobial activity of SP-A/SP-BN is based on the capability of this complex, but not either protein alone, to alter the integrity of bacterial membranes.

12 April 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MMMario Martínez-Florensa
Mario Martínez-Florensa
MAMaría Velasco-De Andrés
María Velasco-De Andrés
OCOlga Cañadas
Olga Cañadas
Víctor Fraile-ÁgredaVíctor Fraile-Ágreda
Víctor Fraile-Ágreda
SCSergi Casadó-Llombart
Sergi Casadó-Llombart
LFLozano Francisco
Lozano Francisco
Sepsis is an unmet clinical need constituting one of the most important causes of death worldwide, a fact aggravated by the appearance of multidrug resistant strains due to indiscriminate use of antibiotics. Host innate immune receptors involved in pathogen-associated molecular patterns (PAMPs) recognition represent a source of broad-spectrum therapies alternative or adjunctive to antibiotics. Among the few members of the ancient and highly conserved scavenger receptor cysteine-rich superfamily (SRCR-SF) sharing bacterial-binding properties there is CD6, a lymphocyte-specific surface receptor. Here, we analyze the bacterial-binding properties of three conserved short peptides (11-mer) mapping at extracellular SRCR domains of human CD6 (CD6.PD1, GTVEVRLEASW; CD6.PD2 GRVEMLEHGEW; and CD6.PD3, GQVEVHFRGVW). All peptides show high binding affinity for PAMPs from Gram-negative (lipopolysaccharide; Kd from 3.5 to 3,000 nM) and Gram-positive (lipoteichoic acid; Kd from 36 to 680 nM) bacteria. The CD6.PD3 peptide possesses broad bacterial-agglutination properties and improved survival of mice undergoing polymicrobial sepsis in a dose- and time-dependent manner. Accordingly, CD6.PD3 triggers a decrease in serum levels of both pro-inflammatory cytokines and bacterial load. Interestingly, CD6.PD3 shows additive survival effects on septic mice when combined with Imipenem/Cilastatin. These results illustrate the therapeutic potential of peptides retaining the bacterial-binding properties of native CD6.

7 September 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
JCJuan Manuel Coya
Juan Manuel Coya
Víctor Fraile-ÁgredaVíctor Fraile-Ágreda
Víctor Fraile-Ágreda
LTLidia de Tapia
Lidia de Tapia
BGBelén García-Fojeda
Belén García-Fojeda
ASAlejandra Sáenz
Alejandra Sáenz
CCCristina Casals
Cristina Casals
The exploration of therapies combining antimicrobial lung proteins and conventional antibiotics is important due to the growing problem of multidrug-resistant bacteria. The aim of this study was to investigate whether human SP-A and a recombinant trimeric fragment (rfhSP-A) have cooperative antimicrobial activity with antibiotics against pathogenic Gram-negative bacteria. We found that SP-A bound the cationic peptide polymyxin B (PMB) with an apparent dissociation constant (KD) of 0.32 ± 0.04 µM. SP-A showed synergistic microbicidal activity with polymyxin B and E, but not with other antibiotics, against three SP-A-resistant pathogenic bacteria:Klebsiella pneumoniae, non-typableHaemophilus influenzae(NTHi), andPseudomonas aeruginosa. SP-A was not able to bind toK. pneumoniae, NTHi, or to mutant strains thereof expressing long-chain lipopolysaccharides (or lipooligosaccharides) and/or polysaccharide capsules. In the presence of PMB, SP-A induced the formation of SP-A/PMB aggregates that enhance PMB-induced bacterial membrane permeabilization. Furthermore, SP-A bound to a molecular derivative of PMB lacking the acyl chain (PMBN) with aKDof 0.26 ± 0.02 μM, forming SP-A/PMBN aggregates. PMBN has no bactericidal activity but can bind to the outer membrane of Gram-negative bacteria. Surprisingly, SP-A and PMBN showed synergistic bactericidal activity against Gram-negative bacteria. Unlike native supratrimeric SP-A, the trimeric rfhSP-A fragment had small but significant direct bactericidal activity againstK. pneumoniae, NTHi, andP. aeruginosa. rfhSP-A did not bind to PMB under physiological conditions but acted additively with PMB and other antibiotics against these pathogenic bacteria. In summary, our results significantly improve our understanding of the antimicrobial actions of SP-A and its synergistic action with PMB. A peptide based on SP-A may aid the therapeutic use of PMB, a relatively cytotoxic antibiotic that is currently being reintroduced into clinics due to the global problem of antibiotic resistance.